golimumab
1 product
1 abstract
1 target
Target
tumor necrosis factorAbstract
TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC.Org: Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Research Center,
Product
SIMPONI + MTX